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Background: In organisms where the two sexes have unequal numbers of X-chromosomes, the expression of
X-linked genes needs to be balanced not only between the two sexes, but also between X and the autosomes. In
Drosophila melanogaster, the Male-Specific Lethal (MSL) complex is believed to produce a 2-fold increase in
expression of genes on the male X, thus restoring this balance.
Results: Here we show that almost all the genes on the male X are effectively compensated. However, many genes
are compensated without any significant recruitment of the MSL-complex. These genes are very weakly, if at all,
affected by mutations or RNAi against MSL-complex components. In addition, even the genes that are strongly
bound by MSL rely on mechanisms other than the MSL-complex for proper compensation. We find that long,
non-ubiquitously expressed genes tend to rely less on the MSL-complex for their compensation and genes that in
addition are far from High Affinity Sites tend to not bind the complex at all or very weakly.
Conclusions: We conclude that most of the compensation of X-linked genes is produced by an MSL-independent
mechanism. Similar to the case of the MSL-mediated compensation we do not yet know the mechanism behind
the MSL-independent compensation that appears to act preferentially on long genes. Even if we observe
similarities, it remains to be seen if the mechanism is related to the buffering that is observed in autosomal
aneuploidies.
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In organisms where females have two X-chromosomes and
males have only one, some type of dosage compensation is
needed. The expression of X-linked genes needs to be bal-
anced not only between the two sexes, but also between X
and the autosomes, in order to maintain the balance of
metabolic networks [1-3]. In Drosophila melanogaster, this
is achieved by an approximately 2-fold increase in expres-
sion of the genes on the male X-chromosome. It is com-
monly stated in the literature that the Male-Specific Lethal
(MSL) complex is responsible for this 2-fold increase by
binding to expressed genes on the male X [4-8]. The MSL-
complex consists of five protein components, namley the
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article, unless otherwise stated.first (MOF), Maleless, Male-Specific Lethal 1 (MSL1),
Male-Specific Lethal 2 (MSL2), and Male-Specific Lethal
3 (MSL3), and two non-coding RNAs (roX1 and roX2)
[9,10]. The components of the MSL-complex clearly have
important functions since mutations are male-specific le-
thal. However, many (10–25%) of the expressed genes on
the male X are not bound by the complex [11-14]. There
have been different explanations for this; the most com-
mon explanation has been that these unbound genes are
only transiently bound by the complex and thus binding
escapes detection [15]. Although it has generally been as-
sumed that the genes that are unbound but still expressed
are dosage compensated, this assumption has not been
investigated thoroughly on a genome-wide level. Zhang
et al. found that genes on the X-chromosome were, on
average, dosage compensated approximately 1.35-fold by
an MSL-dependent mechanism, irrespective of the gene
dose, in a male cell-line [16]. It has been speculated thatCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
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mediated by a more general buffering mechanism acting
on all genomic regions that are present in single copy
[16-19]. The idea that the MSL-complex is not responsible
for the bulk of chromosome X dosage compensation
has been previously proposed by Birchler et al. [20-22],
suggesting that an “inverse dosage effect” causes an up-
regulation of the single male X-chromosome mainly
through the loss of negative regulators. However, to
date, no study has attempted a genome-wide scale cor-
relation between compensation and the binding of the
MSL-complex at the individual gene level.
If the MSL-complex is the mediator of the full, 2-fold,
dosage compensation, we would expect to observe an
approximately 2-fold reduction in the expression of
genes on the X-chromosome if components of the com-
plex are removed. Arguing against this prediction,
several studies have shown that expression of male X-
linked genes is only reduced to about 80% of the normal
value after RNAi knock-down or mutation of MSL-
complex components [5,6,23,24].
In this paper, we use publicly available data which we
combine and present in novel ways in order to investi-
gate the proportion of expressed genes on the male X
that are dosage compensated. We also analyze how
much the dosage compensated genes are dependent on
the MSL-complex.
Results and discussion
Most expressed genes on the male X are dosage
compensated
We first set out to investigate how many of the expressed
genes on the male X-chromosome are dosage compen-
sated. To do this, we used the (to our knowledge) only
available set of genome wide expression data from a single
tissue (salivary glands) where both males and females were
studied separately [8]. It is important to perform this ana-
lysis on a sample including as few different cell types as
possible since we would otherwise be unable to distinguish






















Figure 1 Male minus female expression in salivary glands (log2) of all
Dotted grey lines indicate ± one standard deviation from the mean of chroexample, variation in cell type proportions. Similarly, we
cannot use cell-lines as male and female cell-lines could
have very different origins. Since unexpressed genes or
genes expressed below the detection limit of the technique
(in this case array) will appear to be dosage compensated,
we excluded all genes not expressed in males and/or fe-
males, using the same approach as in previous studies
[18,25,26]. We next plotted the male/female expression ra-
tio across the major chromosome arms (chromosome X
and 3L are shown in Figure 1, the other major chromo-
some arms are shown in Additional file 1: Figure S1) and
calculated the ratio mean and standard deviation (the
male/female ratio appears to be normally distributed on
all chromosomes). Interestingly the chromosomes show
a similar mean and standard deviation (mean −0.044
to −0.003, SD 0.33 to 0.51). The X-chromosome seems
to be well compensated (mean −0.020) and shows low
variation in the expression ratio (SD 0.38).
We then defined dosage compensated genes as genes
on chromosome X that are expressed in both males and
females and where the log2 ratio was within one standard
deviation of the mean for an autosomal chromosome; for
this study we used chromosome 3L (> − 0.55, <0.47).
According to this definition, 90.4% of all expressed genes
(n = 882) on the X-chromosome are dosage compensated
(Figure 1), a value which is comparable to those of the au-
tosomes where 88.2% to 91.1% of the genes are expressed
at the same levels in males and females.
Based on these results, we conclude that most genes
on the male X-chromosome are effectively compensated
and that there are similar numbers of differentially
expressed genes when comparing males and females
across all major chromosome arms. Although this effect
has not been formally demonstrated previously, it is in
line with current opinion in the field. Expression levels
in males and females have been compared in other stud-
ies [24,27]. However, these comparisons were done using
whole flies, making it impossible to separate dosage
compensatory effects acting on individual genes from






















genes expressed in both sexes along chromosomes X and 3L.
mosome 3L.




































































Figure 2 A significant part of the genes on the X chromosome
are dosage compensated, unbound by MOF and not H4K16
acetylated in salivary glands. Male minus female expression (log2)
of all genes expressed in both sexes plotted versus MOF gene
binding values on (A) the X-chromosome and (B) chromosome 3L.
Horizontal dotted grey lines indicate ± one standard deviation from
the mean expression ratio for chromosome 3L and vertical lines the
mean MOF binding on chromosome 3L plus one standard
deviation. (C) Average H4K16ac in four non-overlapping groups
with different levels of MOF binding, (Unbound n = 122, >3 n = 220,
>4 n = 227, >5 n = 227).
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direct comparison of expression effects at an individual
gene level with binding levels of the MSL-complex.
About 15% of expressed genes on male X are dosage
compensated but unbound by MSL and have significantly
reduced levels of H4K16 acetylation
Various figures have been reported for the number of
genes that are expressed but not bound by MSL [11-14].
To determine how many of the compensated genes are
significantly bound by the MSL-complex we used avail-
able MOF binding data from male salivary glands [28].
MOF binds to both the promoters and the gene bodies
of MSL-targeted genes on the X-chromosome [26,29,30].
After determining the extent of binding to all gene bod-
ies excluding the first 200 bp of exon sequence (see
Methods), we plotted the male/female expression ratio
versus MOF binding for all chromosomes (chromosome
X and 3L are shown in Figure 2A,B).
To determine which genes undergo binding by MOF
to the gene body, we calculated the mean and standard
deviation of MOF binding to expressed genes on chromo-
some 3L (MOF binding values were found to be normally
distributed on 3L). Genes on X with a binding value
higher than the 3L mean plus one standard deviation
(mean = 1.00, SD = 0.48) were considered to be bound.
This cut-off probably identifies some unbound or very
weakly bound genes as bound, since 147 genes on chromo-
some 3L would be considered bound by this definition. It
is known that MOF is also bound to autosomes as part of
the Non-Specific Lethal complex [31], but since this bind-
ing is to the promoters of genes it will not influence our
calculated gene binding values for MOF (see Methods).
Using this definition, we find that 122 genes on the male
X-chromosome are dosage compensated although not
bound at any detectable level by the MSL-complex. The
fact that many expressed genes are not bound by the MSL-
complex has been reported several times. However, the
level to which these genes are compensated has been un-
known [29,32,33]. The usual explanation for the lack of
MSL binding to these expressed genes has been that they
only transiently interact with the complex and they do
show H4K16 acetylation marks. However, when we look at
the H4K16ac data from male salivary glands [8] in the gene
bodies of all dosage compensated X-linked genes, we see
drastically reduced levels of acetylation of the genes that
we classified as unbound but still compensated (Figure 2C).
Although we cannot exclude the possibility of the MSL-
complex influencing these genes on the basis of these re-
sults, we argue that it is very unlikely.
The data we are using is from salivary glands which
have multiple copies of each chromosome. It is known
that parts of the genome are under-replicated in salivary
glands and the female X-chromosome have more suchregions when compared to the male X-chromosome
[34,35]. It is therefore possible that MSL unbound genes
in our data set will appear to be compensated, when in
fact they may have similar copy numbers in males and
females. To investigate this, we first counted how many
expressed and compensated genes map to the under-
replicated regions on the X-chromosome reported by
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and compensated genes map to under-replicated re-
gions, which is very similar to the 28% of strongly bound
(MOF binding value >5), expressed and compensated
genes that map to under-replicated regions. In addition
we calculated the copy number ratio between males and
females of all compensated genes using the input reads
of the MOF ChIP-seq experiments. The male and female
input samples varied in sequencing depth but we ob-
served that on average the X-linked genes clearly have a
lower male to female ratio when compared to the auto-
somes (Man-Whitney U Test, P <0.05). The unbound
compensated genes did not have more similar copy
number in males versus females. In this analysis we saw
a weak trend that the more MOF bound the higher the
male/female copy number ratio. We therefore conclude
that the compensation of the MSL unbound genes is not
caused by similar copy numbers in males and females.Genes unbound by MSL but still compensated are not
affected by MSL RNAi
In order to determine whether the genes identified as
unbound (or bound below the detection limit) by MSL
are in fact independent of the MSL-complex, we turned
to MSL-complex component RNAi knock-down and
mutant data available from S2 cells and male larvae, re-
spectively. Although these data sets are not from salivary
glands, we and others have shown that MSL-complex
binding is extremely similar between different cell types
[13,26,32] (Additional file 2: Figure S2). Although the
MSL binding levels of some genes are likely to differ be-
tween, for example, S2 cells and salivary glands, we be-
lieve that comparison of data from these sources will beA
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Figure 3 MOF unbound genes in salivary glands are less affected in M
lines (log2 expression of MOF RNAi-GFP RNAi, Unbound n = 86, >3 n = 208,
(log2 expression of roX1 roX2-WT, Unbound n = 100, >3 n = 212, >4 n = 205meaningful (we exclude genes that are not expressed in
the wild-type or mock RNAi).
When we correlate the effect of RNAi knock-down or
mutations in MSL-complex components with MOF
binding to compensated genes, we see that the expres-
sion of genes that are unbound but still compensated is
very weakly affected by MSL (Figure 3; Additional file 3:
Figure S3). In the mutant data sets from male larvae,
the unbound genes are virtually unaffected, and in the
RNAi experiments these genes show a weak reduction
in expression (significantly different from autosomes,
four RNAi data sets, Man-Whitney U Test, all P <0.05).
The small effect on the unbound genes in the RNAi ex-
periments could indicate that they are weakly bound
(below what we can detect with ChIP-seq) or that these ef-
fects are secondary gene network effects. We note that the
most strongly bound genes show less reduction in expres-
sion in some experiments (Additional file 3: Figure S3). In
the RNAi knock-down experiments this could be due to
the fact that knock-down is not complete and that weakly
bound genes will lose the MSL-complex before those that
are more strongly bound. If so, that would make it unlikely
that the genes we defined as unbound have weak inter-
actions with the MSL-complex as those should be lost
first. Unbound genes also score lower than bound genes
(Man-Whitney U Test, all P <0.05) on sequence signa-
tures previously found to be enriched in MSL bound
genes in S2 cells [26], further supporting that unbound
expressed genes do not recruit MSL. We note that the
genes which show the strongest reduction in expression
are still expressed at about 80% of wild-type levels. We
conclude that a significant proportion of dosage compen-
sated genes on the male X-chromosome is compensated


































 95% Conf. Interval 
SL-complex mutants/knock-downs. (A) Expression in S2 MOF RNAi
>4 n = 222, >5 n = 226). (B) Expression in roX1 roX2 mutant larvae
, >5 n = 205).
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salivary glands, these genes (such as runt, giant and but-
tonhead) are either not expressed according to our defini-
tions, or, if expressed, bound by MOF.MSL independent mechanisms probably play an
important role in compensating the male X-chromosome
An MSL-independent mechanism probably also plays a
significant role for MSL-bound genes, as the latter are
only mildly affected by the loss of MSL-complex compo-
nents. This was previously observed by (for example)
Zhang et al. [16], and could be explained either by the
presence of a general buffering mechanism, which recog-
nizes genomic regions present in fewer copies and which
acts on all chromosomes [18,25], or by gene network ef-
fects [42]. The general buffering of autosomal deficiencies
reported by Lundberg et al. showed stronger buffering of
long genes [18]; if the same mechanism also acts on the
X-chromosome, we expect that long genes would be less
MSL dependent. We found that unbound genes are on
average much longer than bound genes (Figure 4A)
suggesting that long genes are less dependent on the
MSL-complex.
If this mechanism applies, we would expect long
bound genes to be less affected by reduction or loss of
the MSL-complex. When long genes (>10 kb, the ap-
proximate median length of unbound genes) are com-
pared to short genes (<10 kb), MSL-bound long genes
are less affected by RNAi/mutation of MSL compo-
nents (five data sets, Man-Whitney U Test, all
P <0.05), with the exception of the MSL-3 RNAi which
was investigated by Kind et al. [29]. The differences be-
tween long and short genes are most prominent in the
msl2 and roX1 roX2 mutant datasets. For bound genes,
there is a correlation between transcript length and ex-










































Figure 4 Long genes are less dependent on the MSL-complex. (A) Ave
genes with different levels of MOF binding in salivary glands (Unbound n =
mutant male larvae (relative to wild-type) plotted versus transcript length.We conclude that long X-linked genes are less, if at all,
affected by loss of the MSL-complex.
The finding that long genes are less dependent on
MSL for dosage compensation is intriguing and is in line
with the fact that it has previously been shown that
MSL-bound genes are mainly housekeeping genes [12].
We therefore looked at the genes that are unbound but
still compensated and found that only 29% of them are
classified as housekeeping (according to the definition in
[25]) compared to 70% of the bound genes. Kharchenko
et al. found that long genes are preferentially found in
regions enriched for the enhancer type of chromatin
(chromatin state 3) [43]. We speculate that long genes
are more dynamically regulated and are less dependent
on the MSL-complex for compensation of their expres-
sion in males. The binding of MSL to some long genes
is probably due to their proximity to high affinity sites.
Unbound long genes (>10 kb) are on average posi-
tioned 48 kb from a high affinity site (defined by com-
bining the sites reported by Alekseyenko et al. [7] and
Straub et al. [44]) while bound long genes are on aver-
age 19 kb away.
Recently, two contradictory studies tried to identify the
mechanism behind MSL-dependent compensation [8,45].
The results of Larschan et al. indicated enhanced elong-
ation efficiency, but it was later questioned whether
enhanced elongation efficiency on the X-chromosome
could be demonstrated using the same data [45]. When
chromosome X is compared to individual autosomes, no
enhanced elongation efficiency can be seen [8,46]. Conrad
et al. provided evidence for increased RNA Pol2 initiation
on MSL-bound genes [8]. Recently, problems with the
analysis pipeline applied to these data have been pointed
out [47-49]. However, even after correcting for the pre-
processing issues, an approximately 20% increase of Pol2
initiation on MSL-bound genes was observed [47-49].
This is compatible with an MSL-dependent mechanism0.5 5 50
Transcript length in kb
rage transcript length in four non-overlapping groups of expressed
122, >3 n = 220, >4 n = 227, >5 n = 227). (B) Expression in msl2
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results in only an approximately 20% drop in expression.
Although additional evidence is needed, it has been
proposed that the MSL-complex sequesters MOF from
autosomes [21,22] and constrains its activity on the X-
chromosome [20,50]. Clearly, the MSL-complex has an
essential function, as mutations affecting its components
are male-specific lethal, and we speculate that this func-
tion is to enhance the expression of genes that lack effect-
ive feed-back regulation; these seem to be mostly short
housekeeping genes. Although the mechanisms of the
MSL independent compensation mechanism remain elu-
sive, they clearly make a significant contribution to dosage
compensation of the X-chromosome and merit more fo-
cused investigation.Conclusions
The Drosophila male X-chromosome is extremely well
compensated and a significant number of genes are com-
pensated without being bound by any detectable levels of
MSL-complex. Taken together with the fact that even the
most strongly affected genes (those with robust MSL
binding) in MSL mutants/knock-downs are still expressed
at about 80% of wild-type (50% is expected if the MSL-
complex is the only player in dosage compensation), the
majority of the dosage compensation of all male X-linked
genes is likely mediated by an MSL-independent mech-
anism. Similar to the MSL-mediated part of dosage
compensation, we do not yet know the mechanism be-
hind the MSL-independent compensation other than
that it appears to act preferentially on long genes. We
hope that future studies not exclusively focused on the
MSL-complex will shed light on these important MSL-
independent mechanisms.Methods
Micro-array expression data analysis
Gene expression levels in wild-type, RNAi, and mutant
samples were computed from Affymetrix .CEL files of raw
gene expression data using Robust Multi-Array Average
[51] with the Bioconductor “affy” package [52]. Each pro-
beset was then mapped to the genomic Release 5 coordi-
nates using the latest library files from Affymetrix. Only
probeset mapping to a single gene were included in this
study (in the main text these are referred to as genes) and
the medians of biological replicates were used for down-
stream analysis. We defined expressed genes as those with
expression values of 6 or more (log2) as previously de-
scribed [18,25,26]. The following datasets were used for
the analysis: (male, female wild-type – E-MEXP-3506, mof,
msl1, msl3 RNAi – E-MEXP-1505, msl2 RNAi – http://
compbio.med.harvard.edu/Supplements/GD05.html, msl2
mutant – GSE12054, roX1 roX2mutant – GSE3990).ChIP data analysis
Reads from MOF and H4K16ac immunoprecipitation
(IP) and input samples (E-MTAB-911) were aligned
against the Drosophila melanogaster reference sequence
(release 5) using the Bowtie software package [53], map-
ping reads only to unique locations in the genome (pa-
rameters: -n 2 –k 1 --best). Read counts per nucleotide
were calculated and median smoothed using a window
size of 10 bp, and smoothed read counts were extracted
at intervals of 10 bp across the genome. For each pos-
ition in the IP sample with at least one mapped read, a
ratio of IP-input (on a log2 scale) was calculated. If the
read count in the input was below the read-count mean
(in the input sample) it was set to the mean. If the input
mean was below four the minimum input value was set
to four (to avoid division by near-zero values). All ratio
values were then adjusted by reducing each value by the
median of the ratios. This linear adjustment was carried
out in order to compensate for differences in IP and in-
put sequencing depth. Ratio values were further median
smoothed using a window size of 200 bp. Windows with
fewer than 10 data points were discarded. Gene binding
values for MOF and H4K16ac from salivary glands were
calculated by first extracting all data points (at 10 bp
resolution) within annotated exons of each gene. If the
number of data points for a given gene exceeded 10,
they were sorted and the gene binding value calculated
as the mean of the 50% highest values as described by
Johansson et al. [46], with the exception that here we ex-
cluded the first 200 bp exonic sequence of each gene. In-
trons were excluded since both MOF and H4K16ac are
enriched in exons. Using the top 50% of the exon values
makes the mean less sensitive to alternatively spliced
exons. We exclude genes with fewer than 10 data points
to avoid uncertain binding values from short genes. We
also calculated gene binding values for MOF, MSL1, and
MSL3 in S2 cells from data (E-MEXP-1508) in the study
by Kind et al. [29].
To calculate copy number ratio for each gene between
males and females, read counts per nucleotide in male
and female input samples were first median smoothed
using a window size of 1 kb and smoothed read counts
were extracted at intervals of 10 bp across the genome.
All such 10-step positions within compensated genes
were averaged and a male/female ratio (on a log2 scale)
was calculated.
Statistical analysis and visualization of data
All statistical analyses and visualizations were performed
using Statistica (Statsoft, USA) and Evince (UmBio,
Sweden). Transcript length was calculated, using Flybase
annotation Release 5.43 [54], as the difference between
Gene Start and End positions. To calculate the distances
between genes and High Affinity Sites (HAS), we used
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Alekseyenko et al. [7] and Straub et al. [44]. Before
normalization, all data sets were tested for skewness as
described by Landfors et al. [55].
Additional files
Additional file 1: Figure S1. Male minus female expression (log2) of all
dosage compensated genes plotted versus MOF gene binding values on
the X chromosome (salivary gland data). Coloring from red (strong) to
dark blue (weak) based on MOF, MSL-1 and MSL-3 gene binding values
in the S2 cell-line. All data are in log2.
Additional file 2: Figure S2. Expression of genes with variable MOF
gene binding values in A) msl2 mutant versus wild type larvae (Unbound
n = 93, >3 n = 208, >4 n = 211, >5 n = 202), B) msl2 RNAi versus control
RNAi in S2 (Unbound n = 69, >3 n = 205, >4 n = 222, >5 n = 224), C) msl1
RNAi versus control RNAi in S2 (Unbound n = 86, >3 n = 208, >4 n = 218,
>5 n = 223), and D) msl3 RNAi versus control RNAi in S2 (Unbound
n = 86, >3 n = 208, >4 n = 222, >5 n = 226). All data are in log2.
Additional file 3: Figure S3. Male minus female expression in salivary
glands (log2) of all genes expressed in both sexes along chromosomes
2L, 2R and 3R.
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